Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.63 |
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | RAF1 | P04049 | 7/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282376 | 0.90 | CDK8 (0.61) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL282287 | 0.89 | RAF1 (0.56) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL938819 | 0.81 | KDR (0.70) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL10073788 | 0.80 | KDR (0.59) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL5899269 | 0.80 | CDK8 (0.74) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL12319881 | 0.80 | KDR (0.76) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL16621285 | 0.79 | RAF1 (0.69) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL30462521 | 0.78 | RAF1 (0.73) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL936533 | 0.78 | RAF1 (0.73) | BRAFKDRRAF1PDGFRBKIT | |
| SCHEMBL21750962 | 0.78 | KDR (1.00) | BRAFKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428506-B1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | BRAF 1216/4885KDR 3633/4885RAF1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.